AMNEAL PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $4.70 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-02-27
- AMNEAL PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2018-12-31 was $400.00K.
- AMNEAL PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2018-09-30 was $1.40M.
- AMNEAL PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $4.70M, a 161.11% increase from fiscal 2024.
- AMNEAL PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $1.80M, a 800.00% increase from fiscal 2023.
- AMNEAL PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $200.00K, a 100.00% increase from fiscal 2022.
- AMNEAL PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $100.00K, a 90.91% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2025-12-31 | $4.70M 10-K · filed 2026-02-27 | |||
| 2024-12-31 | $1.80M 10-K · filed 2025-02-28 | |||
| 2023-12-31 | $200.00K 10-K · filed 2024-03-14 | |||
| 2022-12-31 | $100.00K 10-K · filed 2023-03-03 | |||
| 2021-12-31 | $1.10M 10-K · filed 2022-03-01 | |||
| 2020-12-31 | $200.00K 10-K · filed 2021-03-01 | |||
| 2019-12-31 | $1.00M 10-K · filed 2020-03-02 | |||
| 2018-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $1.80M derived: sum of 2 quarters · filed 2019-03-01 | $3.00M 10-K · filed 2019-03-01 | |
| 2018-09-30 | $1.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $2.60M 10-Q · filed 2018-11-07 | ||
| 2018-06-30 | $1.20M 10-Q · filed 2018-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |